Initiator Pharma A/S (“Initiator Pharma” or “the Company”) has applied for and received conditional approval for admission to trading of its shares on Nasdaq First North Growth Market Stockholm (“Nasdaq First North”) which is operated by Nasdaq Stockholm AB. As a result, the Company’s application for delisting has also been approved by Spotlight Stock Market. The last day for trading for the Company´s shares on the Spotlight Stock Market is October 22, 2021. The first day of trading of the Company’s shares on Nasdaq First North is October 25, 2021. Shareholders in Initiator Pharma do not have to take any action in connection with the list change from Spotlight to Nasdaq First North.
The Company’s shares are currently traded on the Spotlight Stock Market. Due to the list change, the Company has prepared an Information Memorandum that will be published on the Company’s website through a press release before the first day of trading on Nasdaq First North. The Information Memorandum has only been prepared in connection with the application for admission to trading of the Company’s shares on Nasdaq First North and does not contain any offer to the public to subscribe or otherwise acquire shares or other financial instruments in the Company, either in Denmark, Sweden or in any other jurisdiction.
The Company’s shares will continue to be traded under the short name INIT on Nasdaq First North.
Redeye AB has been appointed the Company’s Certified Adviser on Nasdaq First North. In connection with the list change, DLA Piper Denmark and DLA Piper Sweden has acted as the Company’s legal advisor.
For additional information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035 E-mail: [email protected]
The information was submitted for publication, through the agency of the contact person set out above on 8 October 2021 at 09:40.
About Initiator Pharma
Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs – the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition. Initiator Pharma is listed on Spotlight Stockmarket (ticker: INIT).